LPCN · Lipocine Inc. Common Stock
View on chartInsiders & Stakes
| John W. Higuchi Director | ▲ Buy | Open Market | 241,365 Shares held | 9/30/2026 | View profile |
| Mahesh Patel V CEO and President | ▲ Buy | Open Market | 160,679 Shares held | 4/6/2026 | View profile |
| Spyros Papapetropoulos Director | ▲ Buy | Open Market | 21,739 Shares held | 11/22/2022 | View profile |
| Richard Dana Ono Director | ▲ Buy | Open Market | 14,125 Shares held | 3/20/2023 | View profile |
| Krista Fogarty Principal Accounting Officer | ▲ Buy | Grant | 1,727 Shares held | 3/8/2024 | View profile |
Transaction History
| John W. Higuchi | ▲ Buy | Open Market | 15,970 | $36K | 9/30/2026 |
| John W. Higuchi | ▲ Buy | Open Market | 9,037 | $19K | 9/29/2026 |
| John W. Higuchi | ▲ Buy | Open Market | 12,561 | $27K | 9/28/2026 |
| John W. Higuchi | ▲ Buy | Open Market | 40,000 | $81K | 4/7/2026 |
| John W. Higuchi | ▲ Buy | Open Market | 123,000 | $252K | 4/6/2026 |
| Mahesh Patel V | ▲ Buy | Open Market | 25,000 | $51K | 4/6/2026 |
| Mahesh Patel V | ▲ Buy | Open Market | 25,000 | $51K | 4/2/2026 |
| Mahesh Patel V | ▲ Buy | Grant | 4,893 | $0 | 3/8/2024 |
| Krista Fogarty | ▲ Buy | Grant | 991 | $0 | 3/8/2024 |
| Mahesh Patel V | ▲ Buy | Open Market | 8,706 | $44K | 5/25/2023 |
| Mahesh Patel V | ▲ Buy | Open Market | 150,000 | $48K | 3/24/2023 |
| Richard Dana Ono | ▲ Buy | Open Market | 4,000 | $1K | 3/20/2023 |
| Mahesh Patel V | ▲ Buy | Open Market | 50,000 | $17K | 3/17/2023 |
| Spyros Papapetropoulos | ▲ Buy | Open Market | 21,739 | $10K | 11/22/2022 |
| Mahesh Patel V | ▲ Buy | Open Market | 75,000 | $29K | 11/14/2022 |
| Mahesh Patel V | ▲ Buy | Open Market | 100,000 | $41K | 9/27/2022 |
| Krista Fogarty | ▲ Buy | Open Market | 12,500 | $11K | 5/17/2022 |
| Mahesh Patel V | ▲ Buy | Open Market | 50,000 | $38K | 5/16/2022 |
| Mahesh Patel V | ▲ Buy | Open Market | 25,000 | $27K | 11/18/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Lipocine Partner Verity Gets Health Canada Approval for TLANDO
Lipocine's licensing partner, Verity Pharmaceuticals, received Health Canada approval for TLANDO capsules used in testosterone replacement therapy. This regulatory milestone is relevant to Lipocine as it validates the commercial potential of the licensed product. The stock is currently trading near its 52-week high, reflecting strong recent momentum.
Lipocine Partner Verity Gets Health Canada Approval for TLANDO. Lipocine's licensing partner, Verity Pharmaceuticals, received Health Canada approval for TLANDO capsules used in testosterone replacement therapy. This regulatory milestone is relevant to Lipocine as it validates the commercial potential of the licensed product. The stock is currently trading near its 52-week high, reflecting strong recent momentum.